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Acyl-CoA dehydrogenase 9 (ACAD9) is a recently
identified member of the acyl-CoA dehydrogenase
family. It closely resembles very long-chain acyl-
CoA dehydrogenase (VLCAD), involved in mitochon-
drial b oxidation of long-chain fatty acids. Contrary to
its previously proposed involvement in fatty acid
oxidation, we describe a role for ACAD9 in oxidative
phosphorylation. ACAD9 binds complex I assembly
factors NDUFAF1 and Ecsit and is specifically
required for the assembly of complex I. Furthermore,
ACAD9 mutations result in complex I deficiency and
not in disturbed long-chain fatty acid oxidation. This
strongly contrasts with its evolutionary ancestor
VLCAD, which we show is not required for com-
plex I assembly and clearly plays a role in fatty acid
oxidation. Our results demonstrate that two closely
related metabolic enzymes have diverged at the
root of the vertebrate lineage to function in two sepa-
rate mitochondrial metabolic pathways and have
clinical implications for the diagnosis of complex I
deficiency.
INTRODUCTION
Most cellular energy is produced in mitochondria by an intricate
interplay of metabolic enzymes. In brief, fatty acids and pyruvate
are oxidized to produce NADH and FADH2, in turn used by
the oxidative phosphorylation (OXPHOS) system to produce
ATP. Disturbances in any of these pathways will not only affect
energy production, but can also cause accumulation of toxic
metabolites, disturbed calcium homeostasis, increased reactiveCell Meoxygen species production, and apoptosis (Smeitink et al.,
2006).
As the entry point for NADH, complex I (NADH: ubiquinone
oxidoreductase) of the OXPHOS system plays a central role in
mitochondrial metabolism. Its importance is underlined by
the broad spectrum of different pathologies associated with
complex I defects (Distelmaier et al., 2009). The biogenesis of
complex I involves the combination of 45 subunits encoded by
the mitochondrial and nuclear genomes, a process that requires
the aid of specific chaperones (Vogel et al., 2007c). Most of these
have been identified by mutation screening in complex I-defi-
cient patients: mutations in NDUFAF1–4, C20ORF7, and
C8ORF38 cause isolated complex I deficiency (Dunning et al.,
2007; Ogilvie et al., 2005; Saada et al., 2008, 2009; Sugiana
et al., 2008; Pagliarini et al., 2008). In addition, AIF, Ecsit, and
Ind1 are indispensible for complex I assembly and activity
(Vahsen et al., 2004; Vogel et al., 2007b; Sheftel et al., 2009).
The mechanisms by which these proteins aid and regulate the
assembly of complex I remain to be elucidated.
To find proteins involved in the regulation of complex I biogen-
esis, we screened for proteins that associate with NDUFAF1 and
Ecsit. Surprisingly, ACAD9 was one of the top-scoring candi-
dates. This protein was characterized as a member of the acyl-
CoA dehydrogenase family, as it closely resembles very long-
chain acyl-CoA dehydrogenase (VLCAD) (Zhang et al., 2002).
ACAD9 mutations have been implicated in mitochondrial fatty
acid oxidation disorders (He et al., 2007), which does not seem
compatible with a role in oxidative phosphorylation. However,
the ACAD9 sequence has several specific characteristics of
OXPHOS genes. Its promoter contains a duplicated sequence
homologous to the nuclear respiratory factor 1 motive (NRF1)
(He et al., 2007), which is considered a fingerprint for nuclear
genes involved in the biogenesis of the respiratory chain (Evans
and Scarpulla, 1989). It includes cAMP-responsive element tran-
scription factor binding (CREB) sites (He et al., 2007), which have
also been implicated in respiratory processes rather than intabolism 12, 283–294, September 8, 2010 ª2010 Elsevier Inc. 283
Figure 1. ACAD9, Ecsit, and NDUFAF1 Copurify, Colocalize, and Comigrate
(A) Tandem affinity purifications of ACAD9-, Ecsit-, and NDUFAF1-TAP. SDS-PAGEwestern blot immunodetections of ACAD9 (AC9), Ecsit, NDUFAF1 (AF1), and
NDUFS3. L, total cell lysate; E1, eluate 1; E2, eluate 2; , without doxycycline; +, 24 hr with 1 mg/ml doxycycline.
(B) Colocalization of ACAD9, Ecsit, and NDUFAF1. SDS-PAGE immunodetections of Ecsit, NDUFAF1, ACAD9, and controls MTHSP70, ND1, and cytochrome c
(cyt c) after fractionation of HEK293 mitochondria. Lane 1 contains lysed mitochondria (Mito). After sonication of intact mitochondria, the pellet (P) contains
membrane structures and the supernatant (S) contains the mitochondrial matrix and intermembrane space proteins. Carbonate treatment denatures membrane
structures, and peripherally bound proteins are released into the supernatant (S).
(C) Two-dimensional blue native PAGE analysis of a HEK293 mitochondrial lysate shows the comigration of ACAD9, Ecsit, and NDUFAF1, indicated with ENA1
and ENA2. Complex I (1 MDa) is shown using NDUFS3 antibody.
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ACAD9 Is Required for OXPHOS Complex I Biogenesisb oxidation (Gopalakrishnan and Scarpulla, 1994). By contrast, it
lacks a DR1 consensus binding site, used by peroxisome prolif-
erator-activated receptor a (PPARa) to control expression of
enzymes involved in fatty acid oxidation (such as VLCAD,
LCAD, and MCAD) (He et al., 2007; Aoyama et al., 1998).
Moreover, during mitochondrial import, ACAD9 is processed
by a two-step cleavage in which the second step is processed
by mitochondrial intermediate peptidase (MIP), which mostly
processes proteins in the oxidative phosphorylation system
(Isaya et al., 1994; Chew et al., 2000). Altogether, this raises
the question of whether ACAD9 is involved in OXPHOS instead
of fatty acid oxidation.
Here, we show that ACAD9 is specifically required for complex
I assembly, that it has no apparent role in fatty acid oxidation,
and that mutations in its coding sequence cause isolated
complex I deficiency.RESULTS
ACAD9 Binds Complex I Assembly Factors NDUFAF1
and Ecsit
To investigate the mechanism of complex I assembly, we set out
to find proteins that physically interact with complex I assembly
factors NDUFAF1 and Ecsit. To this end, we generated inducible
HEK293 T-REx cells that express NDUFAF1 and Ecsit with
a C-terminal tandem affinity purification (TAP) tag. After 24 hr
of induction, cell lysates were affinity purified, and lysates and284 Cell Metabolism 12, 283–294, September 8, 2010 ª2010 Elsevieeluates were analyzed by western blotting (Figure 1A) and
nanoLC-MS/MS analysis (Table S1 available online).
ACAD9 was copurified with NDUFAF1 and Ecsit (Table S1). To
verify this interaction, we expressed ACAD9-TAP and used this
as bait for affinity purification. Immunodetection confirmed
binding of ACAD9-TAP with NDUFAF1 and Ecsit (Figure 1A).
In addition, we copurified untagged ACAD9, which can be
explained by the fact that ACAD9 forms dimers (Zhang et al.,
2002). Ecsit-TAP copurified with ACAD9 and NDUFAF1, and
NDUFAF1-TAP copurified with ACAD9 and Ecsit (Figure 1A),
implying a tight interaction between the proteins. The presence
of ACAD9- and Ecsit-TAP in both of the noninduced purified
samples is due to trace amount of inducer tetracycline in the
culture serum (Vogel et al., 2007a, 2007b).
ACAD9 is targeted to mitochondria (Zhang et al., 2002). We
studied ACAD9’s submitochondrial targeting and occurrence
in high-molecular weight complexes to characterize the nature
of its interaction with NDUFAF1 and Ecsit. Mitochondrial
fractionation by sonication and carbonate extraction showed
that NDUFAF1, Ecsit, and ACAD9 share a similar affinity to mito-
chondrial membranes (Figure 1B). As controls, integral
membrane protein ND1 remained in the carbonate pellet,
whereas cytochrome c was extracted. Even though ACAD9, Ec-
sit, and NDUFAF1 have no predicted transmembrane helices,
carbonate extraction cannot efficiently release the proteins
from the membrane. This strong affinity for the membrane has
previously been described for NDUFAF1 in Dunning et al.
(2007) and is suggestive of a strong hydrophobic interaction.r Inc.
Figure 2. RNA Interference-Mediated Knockdown of ACAD9,
Ecsit, and NDUFAF1 in HEK293 Cells
(A) SDS-PAGE western blot immunodetections of ACAD9, Ecsit, NDU-
FAF1, and ND1. NDUFS3 and loading control SDHA.
(B) BN-PAGE analysis of complex I in-gel activity (CI-IGA) andwestern blot
immunodetection of loading control SDHA.
(C) BN-PAGE western blot immunodetection of oxidative phosphorylation
complexes I-V.
A#1, A#2, ACAD9; E, Ecsit; N, NDUFAF1, N; U, untreated; M, mock
transfected.
Table 1. Patient Enzyme Activities of the Mitochondrial
Respiratory Chain Complexes Measured in Cultured Skin
Fibroblasts
Enzyme Activitiesa Patient I-1 Patient II-1 Controls
NADH: Q1 oxidoreductasea 0.053 0.058 0.10–0.26
Succinate: cytochrome c
oxidoreductasea
0.24 0.32 0.16–0.44
Decylubiquinol: cyt c
oxidoreductasea
1.46 2.82 1.25–2.62
Cytochrome c oxidaseb 0.95 0.79 0.68–1.19
Citrate synthasec 165 190 144–257
aValues are given in mU per mU cytochrome c oxidase.
b Values are given in mU per mU citrate synthase.
c Values are given in mU per mg protein (mitochondria-enriched fraction).
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ACAD9 Is Required for OXPHOS Complex I BiogenesisSubsequent two-dimensional blue native SDS-PAGE analysis
showed that ACAD9 comigrates with the previously described
high-molecular weight complexes of 500–850 kDa in size that
contain NDUFAF1 and Ecsit (Figure 1C) (Vogel et al., 2007b).
The two observed spots are indicated with ENA1 and ENA2
(for Ecsit, NDUFAF1, and ACAD9).
ACAD9 Knockdown Results in a Decrease of NDUFAF1,
Ecsit, and Complex I
To assess whether ACAD9, like NDUFAF1 and Ecsit, is required
for complex I assembly, we knocked down its expression in
HEK293 cells by RNA interference (Figure 2). Knockdown of
ACAD9 specifically affected complex I in-gel activity (Fig-
ure 2B, CI-IGA) and protein level (Figure 2C, CI-NDUFA9), but
not the protein levels of the other oxidative phosphorylation
complexes (Figure 2C). In addition, individual Ecsit and NDU-
FAF1 knockdowns were performed to analyze the possible
codependence of these three proteins. ACAD9 knockdown
decreased the protein levels of Ecsit and NDUFAF1 (Figure 2A,
A#1 and A#2). Conversely, Ecsit and NDUFAF1 knockdown
decreased ACAD9 levels, although to a lesser extent (Figure 2A,
E and N).Cell MeGene Sequencing in Complex I-Deficient Patients
Reveals Pathogenic Mutations in ACAD9
The specific requirement of ACAD9 for complex I assembly
prompted us to sequence this gene in a cohort of patients
with isolated complex I deficiency. Previous screening in
these patients for mutations in the entire mitochondrial
DNA, nuclear-encoded complex I subunits, and known
assembly factors did not reveal abnormalities. This analysis
uncovered mutations in the ACAD9 gene in two unrelated
patients with isolated complex I deficiency (enzymatic data
in Table 1; case reports in Experimental Procedures).
Patient I-1 was homozygous for c.1553 G > A, resulting in
R518H; patient II-1 was compound heterozygous for two
mutations: c.187 G > T, resulting in a stop codon after 62
amino acids, and c.1237G > A, resulting in E413K (Figures
3A and 3B). We did not observe any of these mutations in
110 controls. Both missense mutations affect highly
conserved amino acids (Figure 3B). Modeling of the muta-
tions in the ACAD9 structure (PDB code 3b96) reveals the
consequence of the E413K and R518H substitutions
(Figure 3C). The R518H mutation is located at the end of an
a helix, and the arginine side chain forms hydrogen bonds
with glutamic acid 592, which is located in the last C-terminal
helix. Substituting argininewith histidinewill disturb the dimer
conformation due to the loss of stabilizing hydrogen bonds.
The glutamic acid (E413) forms a hydrogen bond with residue
arginine 417 at the dimerization surface. If the glutamic acid is re-
placed by the positively charged lysine, this interaction will be
lost, and steric hindrance may occur because lysine has a larger
side chain and repulses arginine (Figure 3C).tabolism 12, 283–294, September 8, 2010 ª2010 Elsevier Inc. 285
Figure 3. Genetic and Molecular Characterization of the c.1553G > A, c.187G > T, and c.1237G > A Mutations
(A) Electropherograms showing the normal sequence of ACAD9 (Wt, top) and the nucleotide changes in fibroblasts of patients I-1 (I-1, bottom) and II-1 (II-1,
bottom).
(B) Conservation of the altered amino acids is shown via clustalW alignments. Asterisks (*) indicate identical amino acids, colons (:) indicate conserved substi-
tutions, and periods (.) indicate semiconserved substitutions.
(C) Model of ACAD9 and the two mutations found in the patients. The two ACAD9 monomers are shown in green and blue (surface view) by element; carbon is
cyan, nitrogen is blue, oxygen is red, and yellow dots indicate hydrogen bonds. The locations of the mutations are indicated with arrows. The left panel highlights
mutation R518H: the arginine and glutamic acid side chains are shown, forming hydrogen bonds. This interaction will be lost when the arginine is substituted
by a histidine (shown in gray). Right panel mutation E413K: the glutamic acid forms hydrogen bonds with arginine 417 at the dimerization surface of ACAD9.
The replacement of glutamic acid by lysine will disturb this interaction and will result in repulsion. Steric hindrance may occur because lysine has a larger
side chain (indicated in gray).
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ACAD9 Is Required for OXPHOS Complex I BiogenesisSDS-PAGE analysis of patient fibroblasts shows that the
ACAD9 protein can be detected in mitochondria of patient I-1,
whereas no ACAD9 protein was detected for patient II-1 (Fig-
ure 4A). Consistent with the results obtained after ACAD9
knockdown (Figure 2A), protein levels of Ecsit and NDUFAF1 in
ACAD9 patient cell lines were decreased (Figure 4A). For both
subjects, fully assembled complex I was variably decreased
(Figures 4B and 4C, CI-IGA and CI-NDUFA9). To verify that this
decrease of complex I was not secondary to a defective b oxida-
tion, we performed a similar analysis in fibroblasts obtained from286 Cell Metabolism 12, 283–294, September 8, 2010 ª2010 Elseviepatientsdeficient forVLCAD,anestablishedmitochondrially local-
ized b oxidation enzyme (P-V1: described in Chegary et al., 2009;
P-V2: GTTAdel799-802, described in Andresen et al., 1999)
(Figure 4B). No decrease in complex I in-gel activity (CI-IGA) or
protein levels of any of the OXPHOS complexes was observed.
Transduction of ACAD9-RFP expressing baculovirus resulted
in a complex I restoration in fibroblasts of both ACAD9 patients
(Figures 4D–4F). Figure 4D shows proper expression of the
RFP-tagged ACAD9 protein and of RFP tagged to the mitochon-
drial import sequence of COX8 (COX8-RFP), which served asr Inc.
Figure 4. The Mutations in ACAD9 Result in Lower Expression and Activity of Complex I, which Is Restored by ACAD9-RFP Baculovirus
Transduction
(A–C) SDS-PAGE and BN-PAGE analysis of complexes I–V in control fibroblasts (C1, C2), fibroblasts from the patients with mutations in ACAD9 (I-1, II-1), and
fibroblasts from patients with mutations in VLCAD (P-V1, P-V2).
(A) SDS-PAGE immunodetection of ACAD9, Ecsit, NDUFAF1, VLCAD, ND1, NDUFS3, and Porin.
(B) BN-PAGE analysis of complex I in-gel activity (CI-IGA) and western blot immunodetection of loading control complex II-SDHA.
(C) BN-PAGE immunodetection of complex I subunit NDUFA9, complex II-SDHA, complex III-core 2, complex IV-COX1, and complex V-subunit a.
(D–F) Complementation of patient fibroblasts. NI, not infected; Cox8, infected with RFP-tagged COX8 leader sequence; AC9, ACAD9-RFP infected. Infections
performed on control, ACAD9 patient (I-1, II-1), and S7 patient (P-S7) fibroblasts.
(D) SDS-PAGE immunodetections of RFP, ND1, and Porin.
(E) BN-PAGE analysis of complex I in-gel activity (CI-IGA) and western blot immunodetection of loading control complex II-SDHA.
(F) BN-PAGE immunodetection of complex I subunit NDUFA9, complex II-SDHA, complex III-core 2, complex IV-COX1, and complex V-subunit a.
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ACAD9 Is Required for OXPHOS Complex I Biogenesisa negative control. For subject I-1, both CI-IGA and fully assem-
bled complex I increased markedly after infection with the
ACAD9-RFP baculovirus. Subject II-1 shows a slight increaseCell Mein CI-IGA and a more apparent increase in fully assembled
complex I (Figures 4E and 4F, CI-IGA and CI-NDUFA9). This
complex I restoration is specific because ACAD9-RFPtabolism 12, 283–294, September 8, 2010 ª2010 Elsevier Inc. 287
Figure 5. Phylogeny and Modeling of ACAD9 and VLCAD
(A) Phylogenetic distribution of ACAD9 and VLCAD (ACADVL). The phylogenetic distribution of ACAD9 is restricted to the vertebrates, and ACAD9 likely arose
from a gene duplication of VLCAD at the root of the vertebrates. Bootstrap values larger than 90/100 are indicated, showing a clear separation between the
ACAD9 and VLCAD orthologous groups.
(B) The ACAD9 dimer (green and blue). Bothmonomers bind a FAD cofactor (yellow). The positions in ACAD9 of the VLCAD-homologous active sites are indicated
with red arrows.
(C) The altered helices mapped on the dimer model. A color code was used to indicate the residues that show the strongest separation between the ACAD9 and
VLCAD orthologous groups, using the program Multi-Relief (Ye et al., 2008), which gives scores varying from 0 to 1, with the residues that show the strongest
separation obtaining a score of 1. Residues with value of 0.8–0.9 are shown in light red, indicative of moderate structural differences between the ACAD9 model
and VLCAD crystal structure; residues with value of 0.9–1 are shown in dark red, indicative of major structural differences between the ACAD9model and VLCAD
crystal structure. In addition, this model highlights the membrane face of the dimer, and the (loosely modeled) mitochondrial targeting sequence, which is most
likely not part of the actual structure. The asterisk indicates the hydrophobic side of the ACAD9 altered helix.
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ACAD9 Is Required for OXPHOS Complex I Biogenesisbaculovirus transduction of an unrelated complex I patient (P-
S7, described in Triepels et al., 1999) gave no effect. Two-dimen-
sional blue native and SDS-PAGE immunodetection shows
a normalization of the distribution of complex I subcomplexes
after infection (Figure S1).
Structural Differences between ACAD9 and VLCAD
ACAD9 shares considerable sequence homology with very long-
chain acyl-CoA dehydrogenase (VLCAD) (47% amino acid288 Cell Metabolism 12, 283–294, September 8, 2010 ª2010 Elsevieidentity and 65% amino acid similarity). An analysis of ACAD9
homologs showed that the phylogenetic distribution of ACAD9
is restricted to the vertebrates (Figure 5A) and that its closest
relative is VLCAD. Thus, the ACAD9 gene likely arose from
a gene duplication of ACADVL (the gene encoding VLCAD) at
the root of the vertebrates (bootstrap values larger than 90/100
are indicated and indicate a clear separation between the
ACAD9 and VLCAD orthologous groups) (Figure 5A), corre-
sponding with a similar analysis performed by Swigonova´ andr Inc.
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ACAD9 Is Required for OXPHOS Complex I Biogenesiscolleagues (Swigonova´ et al., 2009). Multiple sequence align-
ment followed by identification of the region that has the greatest
difference between the ACAD9 and VLCAD orthologous groups
(but that is conserved within each) highlighted a stretch of about
35 amino acids (Figure S2, amino acids 450–485 in ACAD9). By
modeling ACAD9 using the VLCAD crystal structure as
a template, we were able to investigate which part of the struc-
ture corresponds to this difference (McAndrew et al., 2008).
ACAD9 forms a dimeric structure (Figures 5B and 5C) in which
the highlighted 35 amino acids are predicted to form a helices
on the opposite sides of a cleft of the dimer at the membrane
face (see Figures 5B and 5C, ‘‘Altered helices’’). Given their
marked difference with VLCAD and their location on the outside
of the molecule, these helices would be a likely candidate to
explain the new functional interaction partners of ACAD9 relative
to VLCAD. In summary, our bioinformatic analysis suggests that
ACAD9 has evolved from VLCAD in a relatively short evolutionary
period of time, primarily manifested in a stretch of 35 amino acids
that are predicted to form a helix on the surface of the protein.
ACAD9 Is Not Essential for Long-Chain
Fatty Acid Oxidation
After having demonstrated the specific requirement of ACAD9
for complex I assembly and having established the similarities
between ACAD9 and VLCAD, we focused on possible differ-
ences between the two proteins. We have shown that VLCAD
deficiency does not affect complex I (Figure 4B and 4C). More-
over, the expression of VLCAD and MTP remained unchanged
after the knockdown of ACAD9 (Figure S3A). Conversely, VLCAD
knockdown did not affect ACAD9, complex I in-gel activity, or
the protein levels of all oxidative phosphorylation complexes
(Figures S3B–S3D). Thus, ACAD9 knockdown did not interfere
with complex I assembly via disturbed b oxidation, but either
directly or indirectly via NDUFAF1 and Ecsit.
These data suggest that ACAD9 and VLCAD are involved in
two different metabolic processes in mitochondria. One differ-
ence between OXPHOS and b oxidation of fatty acids is their
dependence on mitochondrial DNA: in contrast to four of the
five enzyme complexes of the oxidative phosphorylation system,
b oxidation enzymes do not require constituents encoded by
the mitochondrial DNA. To investigate the effect of the absence
of mitochondrial DNA-encoded proteins on the stability of
NDUFAF1, Ecsit, ACAD9, VLCAD, and MTP, we analyzed rho-
zero cells, which are deprived of mitochondrial DNA. Similar to
complex I subunits NDUFS3 and ND1, NDUFAF1, Ecsit, and
ACAD9 expression levels were strongly decreased in rho-zero
cells (Figure 6A). This contrasts with the mitochondrial b oxida-
tion enzymes VLCAD and MTP and with nuclear DNA-encoded
complex II subunit SDHA, which all appeared unaffected by
the absence of mitochondrial DNA. Thus, directly or indirectly,
stable mitochondrial presence of ACAD9 depends on the pres-
ence of mitochondrial DNA.
To directly investigate a potential role for ACAD9 in long-chain
fatty acid b oxidation, we assessed the first step in this process,
the palmitoyl-CoA dehydrogenase enzyme activity. We deter-
mined this activity after silencing ACAD9 or VLCAD in HEK293
cells (effect of each knockdown shown in Figure S3E). The
data were normalized against short-chain hydroxyacyl-CoA
dehydrogenase activity (SCHAD), a nonvariable control (specificCell Meactivities of both enzymes are shown in Figures S3F and S3G).
ACAD9 knockdown did not affect the dehydrogenation of palmi-
toyl-CoA, whereas VLCAD knockdown resulted in a decrease of
more than 60% (Figure 6B). This supports the established role of
VLCAD in oxidation of this substrate, and it argues against
a primary role for ACAD9 in this process. To investigate whether
ACAD9 is involved in the b oxidation of long-chain fatty acids, we
measured oleic acid oxidation rate in HEK293 cells following
RNAi of ACAD9 or VLCAD. The RNAi led to the (near) absence
of ACAD9 or VLCAD protein (Figure S3H). In VLCAD-silenced
cells, the rate of oleic acid oxidation was decreased by almost
50%. In contrast, oleic acid oxidation was normal in ACAD9-
silenced cells (Figure 6C). In line with these findings, we found
a decreased rate of oleic oxidation only in VLCAD deficient fibro-
blasts, but no changes in the fibroblasts of ACAD9-deficient
patients (Figure 6D).
DISCUSSION
ACAD9 is a member of the Acyl-CoA dehydrogenase family.
These enzymes catalyze the a-b-dehydrogenation of acyl-CoA
esters. Conflicting with its previously proposed role, we describe
an essential function for ACAD9 in the assembly of mitochondrial
complex I. ACAD9 knockdown leads to a severe and specific
decrease of complex I amount and activity. The protein associ-
ates with complex I assembly chaperones NDUFAF1 and Ecsit
in a codependent fashion, similar to what has been observed
for complex I chaperones NDUFAF3 and NDUFAF4 (Saada
et al., 2009). Moreover, we identified pathogenic mutations in
ACAD9 that lead to isolated complex I deficiency in patients
with exercise intolerance, hyperthrophic cardiomyopathy, lactic
acidosis, and failure to thrive. Importantly, in both patients, no
clinical symptoms were apparent that would point to a specific
defect in b oxidation of fatty acids. In patient I-1, total blood
carnitine concentrations were halved, and b-hydroxybutyrate
concentrations were elevated, contrasting with a long-chain
acyl-CoA dehydrogenase defect. A previous report describes
ACAD9 deficiency in three patients presenting with additional
symptoms, including Reye-like syndrome, liver disease and
hypoglycemia, and cardiomyopathy. All patients had mild
chronic neurologic dysfunction (He et al., 2007). At this moment,
the precise contribution of the ACAD9 defect to these cases is
unclear. Nevertheless, we identified mutations in the coding
sequence of the ACAD9 gene and unequivocally proved that
these are the cause of the isolated deficiency of complex I by
complementation.
ACAD9 was first cloned in 2002 and was proposed to play
a role in the b oxidation of long-chain fatty acids based on its
in vitro enzymatic activity and homology to mitochondrial
b oxidation enzyme VLCAD (Zhang et al., 2002; Ensenauer
et al., 2005). Recombinant purified, mature ACAD9 was shown
to have optimal in vitro acyl-CoA dehydrogenase activity with
long-chain saturated as well as unsaturated acyl-CoA esters
(Ensenauer et al., 2005). These substrates are also efficiently
handled by VLCAD, contributing to the first step in the b oxidation
cycle (Aoyama et al., 1995). VLCAD is ACAD9’s closest family
member and ancestor, as shown by our phylogenetic analysis
(Figure 5A). The overlap in substrate specificity fits well with
the 65% amino acid similarity shared between the two proteins.tabolism 12, 283–294, September 8, 2010 ª2010 Elsevier Inc. 289
Figure 6. Investigation of a Putative Role for ACAD9 in Fatty Acid Oxidation
(A) Expression of OXPHOS proteins and b oxidation enzymes in rho-zero cells. SDS-PAGE western blot immunodetection of ACAD9, Ecsit, NDUFAF1, NDUFS3,
ND1, VLCAD, MTP, and SDHA in control (cy73 and 5118#C) and rho-zero cells (rho-0).
(B–D) Palmitoyl-CoA dehydrogenase activity measurements and oleic acid oxidation measurements in ACAD9- and VLCAD-depleted cells.
(B and C) RNA interference-mediated knockdowns of cyclophilin B (CB), ACAD9 (A#1 and A#2), and VLCAD (V#1 and V#2). U, untreated; M, mock transfected.
(B) Followed by palmitoyl-CoA dehydrogenase activity and short chain hydroxylacyl-CoA activity measurements, the ratio was determined for untreated cells,
mock treated cells, and after each knockdown (n = 2 for each condition).
(C) Followed by oleic acid oxidation assay, oxidation rates (pmol/min.mg) for untreated cells, mock treated cells, and after each knockdown. All values are
presented as average ± SD (n = 4 for each condition).
(D) Oleic oxidation assay on control (C), ACAD9 patient (I-1, II-1), and VLCAD patient (P-V1, P-V2) fibroblasts. Oxidation rates in pmol/min.mg. All values are
presented as average ± SD (n = 3 for each condition).
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ACAD9 Is Required for OXPHOS Complex I BiogenesisIn addition, both proteins function as homodimers and are
in close association with the mitochondrial inner membrane
(Ensenauer et al., 2005). In addition, their active residues,
Glu-462 of VLCAD and Glu-426 of ACAD9 (initiating catalysis)
and Trp-249 and Trp-213 of VLCAD and ACAD9 (which have
a role in electron transfer), have been conserved (Zhang et al.,
2002).
Despite the fact that ACAD9 has conserved the ability to
catalyze the a-b-dehydrogenation of acyl-CoA esters, ACAD9
activity has only been measured in vitro in recombinant purified
protein and was 10-fold lower than VLCAD’s specific activity
(He et al., 2007). Moreover, various arguments exist against
a primary role in long-chain fatty acid oxidation in vivo. Most
importantly, here we show that mutations in ACAD9 cause
complex I deficiency and do not cause a defect in the oleic acid
oxidation rate, in contrast to VLCAD deficient patients, which
have a 3- to 4-fold decreased oleic acid oxidation rate, consistent
with earlier reports (Chegary et al., 2009). In addition, in human
VLCADdeficiencycausedbysevere inactivatingmutations, there
is no evidence for compensation by other long-chain acyl-CoA
dehydrogenase activity. Fibroblasts derived from VLCAD-defi-290 Cell Metabolism 12, 283–294, September 8, 2010 ª2010 Elseviecient patients carrying two null alleles do not have residual dehy-
drogenase activity toward palmitoyl- and oleoyl-CoA, which are
bona fide ACAD9 substrates. Nevertheless, ACAD9 is well
expressed in fibroblasts of these patients as well as healthy
controls (Chegary et al., 2009). Furthermore, our HEK293 siRNA
data show that, in contrast to VLCAD silencing, ACAD9 knock-
down does not affect palmitoyl-CoA dehydrogenase activity
(Figure 6B), nor does it decrease the rate of oleic acid oxidation
(Figure 6C). In contrast to the human situation, VLCAD deficiency
in mice is compensated by other long-chain acyl-CoA dehydro-
genaseactivity (Ter Veld et al., 2009). Several studies have shown
that LCAD is responsible for this compensatory activity, and not
ACAD9 (Kurtz et al., 1998; Chegary et al., 2009). Importantly, in
humans, LCADexpression is extremely low, precluding compen-
sation by this enzyme.
Phylogenetic analysis shows that ACAD9 arose at the root of
the vertebrates, most likely as a gene duplication product of
VLCAD. In a relatively short evolutionary time, ACAD9 has
diverged from VLCAD, acquiring a new function in the assembly
of mitochondrial complex I. Alignment of multiple ACAD9 and
VLCAD sequences highlights a stretch of about 35 amino acidsr Inc.
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are located in an a helix on the surface of the protein. In the dimer
conformation, these residues seem to form a hydrophobic cleft
in which another molecule can bind. We hypothesize that these
structural differences between VLCAD and ACAD9 are required
for its function in complex I assembly, an issue that requires
further investigation.
ACAD9mutations result in the accumulation of complex I sub-
complexes. Judging from their size and the fact that these
contain subunits NDUFS2 and ND1, these are most likely sub-
complexes 4 and 5 of the complex I assembly process (as shown
in Figure S1) (Vogel et al., 2007a). These complexes involve the
incorporation of ND subunits. This observation is in agreement
with the finding that NDUFAF1 is required for the incorporation
of certain ND subunits during complex I assembly (Dunning
et al., 2007)
In conclusion, the differences between VLCAD and ACAD9
provide a valuable insight into evolutionary adaptations.
Although ACAD9 has preserved its dehydrogenase active site
and ability to oxidize several chain lengths of acyl-CoA in vitro,
our data strongly support that its in vivo role is primarily in the
assembly of oxidative phosphorylation complex I. These data
also have clinical implications, as isolated complex I deficiencies
should now also be screened for mutations in ACAD9.EXPERIMENTAL PROCEDURES
Patients
Two patients from two unrelated families were included. Index patient 1 is the
only child of a nonconsanguineous Canadian couple (originating from two
neighboring communities). Pregnancy and delivery were uneventful. The first
months of life, she was noted to be a poor feeder. At 8 months of age, she
presented with failure to thrive and hepatomology due to congestive heart
failure. Echocardiography revealed concentric hyperthrophic cardiomyop-
athy. Additional investigations showed elevated blood lactate of 3.1 and 5.1
(0.4–2.2 mM), massively increased lactate and elevated b-hydroxybutyrate
in urine, decreased serum-free carnitine of 8 (23–65 nm/ml/hr) and total carni-
tine of 21 (30–6665 nm/ml/hr). She was treated for cardiac failure and dis-
charged. At 9 months of age, she was admitted with fever and tachypnea.
Lactate was measured at 5.1 and 5.6, and pyruvate was 56 (40–130 mM).
CSF lactate was elevated at 3.6 (0–2.80 mM). Carnitine levels remained
depressed, with free of 8.0 and total of 16. She was placed on supplemental
l-carnitine and subsequent serum, and later plasma carnitine levels have
been normal or elevated. Plasma amino acid analysis revealed an elevated
alanine of 718 (190–400 mM). Biochemical analysis showed an isolated
complex I deficiency in muscle 30 (96–323 nmole/min/mg), which was
confirmed twice in cultured skin fibroblasts. Computerized tomography
revealed normal brain anatomy. At 10 months of age, she was admitted with
vomiting and lethargy as well as tachycardia and tachypnea. She was noted
to have a gallop rhythm and a 3/6 systolic murmur with her liver 4 cm below
the costal margin. Echocardiogram revealed a large pericardial effusion that
was drained using a percutaneous drainage catheter. Carnitine levels were
free 56 and total 80. The effusion resolved, and she was discharged. She
has had no further admissions to the hospital. Her subsequent course has
been uneventful. At 4 years of age, a lactate was recorded at 7.6. She has
had persistent mild elevated lactate levels, 2.39 at 9 years of age and 2.55
at 12 years of age. Throughout this course, her glucose level has been normal.
The patient is currently 18 years, with short stature, exercise intolerance, mild
hearing loss, and mild hyperthrophic cardiomyopathy.
Patient II-1 was born out of a twin pregnancy of a healthy Thai mother and
a German father following 35 weeks of gestation. After 4 months of age,
feeding problems and poor weight gain were observed. At 5 months, patient
II-1 became acutely unwell with a short history of cough breathlessness and
pallor. When admitted, she had anemia (Hb7.0 mmol/l) and moderate meta-Cell Mebolic acidosis. She was diagnosed with encephalopathy and hyperthrophic
cardiomyopathy. The disease course was progressive, leading to multiorgan
failure and death at the age of 6 months. Biochemical analysis of postmortem
muscle showed a reduced complex I activity expressed as citrate synthase
ratio of 0.063 (0.104–0.268), whereas the activities of the other OXPHOS
complexeswere unaffected. Her twin sister at 6months of age became acutely
unwell as well. She also suffered from a progressive organ failure, with enceph-
alopathy and hypertrophic cardiomyopathy as the most prominent clinical
signs and symptoms, and died at the age of 8 months.
Generation of Inducible Cell Lines
All described constructs were cloned using the Gateway system (Invitrogen).
pDONR201Ecsit and the TAP-Destination vectors were constructed as
described (Vogel et al., 2007b). The entire open reading frame (without stop
codon) of ACAD9 (GI:193083151) flanked by Gateway AttB sites was created
by PCR according to the manufacturer’s protocol and cloned into pDONR201
by the use of Gateway BP Clonase II Enzyme Mix. The pDONR201-ACAD9-
vector was recombined with the AcGFP1-destination vector by use of the
LR Clonase II Enzyme Mix (Invitrogen). To obtain the inducible TAP-tagged
cell lines, pDONR201-Ecsit (Vogel et al., 2007b) and pDONR201-ACAD9
vectors were recombined with the TAP-Destination vector (Vogel et al.,
2007b) by use of the LR Clonase II Enzyme Mix (Invitrogen). The obtained
constructs were transfected into Flp-In T-REx HEK293 cells (Invitrogen) by
using SuperFect Transfection Reagent (QIAGEN) according to the manufac-
turer’s manual. The inducible NDUFAF1-TAP cell line was previously
described in Vogel et al. (2007b).
Cell Culture
HEK293 cells were cultured in DMEM (Biowhitaker) supplemented with 10%
fetal calf serum (FCS) (v/v) and 1% penicillin/streptomycin (GIBCO). Inducible
cell lines were selected on 5 mg/ml blasticidin (Invitrogen) and 200 mg/ml
hygromycin (Calbiochem), and for expression of the transgene, 1 mg/ml doxy-
cycline (Sigma Aldrich) was added for 24 hr. Rho-zero cells were cultured and
derived from 143B osteosarcoma cells using either control fibroblast mito-
chondria (5118#C) or 100% wild-type fibroblast mitochondria described in
Corona et al. (2001) (cy 73). Patient skin fibroblasts were cultured in medium
199 supplemented with 10% fetal calf serum, bicarbonate, and antibiotics.
The cells were cultured until confluent.
Tandem Affinity Purification and NanoLC-MS/MS Analysis
The tandem affinity purification (TAP) was performed according the protocol
for the InterPlay Mammalian TAP System (Stratagene). 6 3 107 cells were
used per purification. Proteins were eluted by incubating in 50 mM NH4HCO3
(pH 8.0) at 95C for 5 min twice (eluates 1 and 2). To reduce the amount of
substances in the sample that interfere with nanoLC-MS/MS analysis,
samples were briefly subjected to SDS-PAGE. NanoLC-MS/MS analysis
was performed as described previously with minor modifications (Vogel
et al., 2007b). In brief, proteins were in-gel reduced with 10 mM dithiotreitol
and alkylated with 50 mM iodoacetamide before in-gel digestion with trypsin.
After extraction of the peptides from the gel, samples were desalted and
concentrated using Stage tips (Rappsilber et al., 2003). NanoLC-MS/MS anal-
ysis was performed using an Agilent nanoflow 1100 liquid chromatograph
coupled online via a nano-electrospray ion source (Thermo Fisher Scientific)
to a 7T linear ion trap Fourier transform ion cyclotron resonance mass spec-
trometer (LTQ FT, Thermo Fisher Scientific). Instrument settings are further
explained in Supplemental Experimental Procedures. Mass spectrometric
data files were searched using the database search program Mascot (Matrix
Science Inc., USA, version 2.2). The database used for the searches consisted
of the human RefSeq database (release 33) with addition of the sequences of
the TAP proteins used in this study and known contaminants such as trypsin.
An in-house-developed script was used to parse first-ranked peptides from
theMascot search HTML files and evaluate peptide and protein identifications.
Validation criteria are described in Supplemental Experimental Procedures.
RNA Interference
HEK293 cells (2 3 105) were seeded in 2 ml DMEM supplemented with 10%
FCS (no antibiotics) per well in 6-well plates a day preceding the siRNA trans-
fection. The cells were transfected with siRNA duplex in the presence of 4 mltabolism 12, 283–294, September 8, 2010 ª2010 Elsevier Inc. 291
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achieve a final concentration of 100 nM in a total volume of 2.4 ml. Control:
cyclophilin B (Thermo Fisher Scientific), ACAD9 #1 antisense strand: 50-GAG
GCUCAGUGAAUUUGGA dTdT-30, ACAD9 #2 antisense strand: 50-CCUUC
UGCGUGGAAGCUUA dTdT-30, Ecsit antisense strand: 50-AUUGAUGUC
AAACUCGUAG dTdT-30, NDUFAF1, antisense strand: 50-UAACUAUACAUCU
GAUUCG dTdT-30, VLCAD #1 antisense strand: 50-GGUGUUCUUUGAUGGA
GUA dTdT-30, #2 antisense strand 50-GCAUCGGUUUCAAAGGCAU dTdT-30,
#3 antisense strand 50-GGAUGGUUAUGCUGCAGUA dTdT-30. The cells were
incubated at 37C in a CO2 incubator for 72 hr, and a second cycle of transfec-
tion was performed.
Blue Native, SDS-PAGE, and In-Gel Activity Assays
Blue native gradient (5%–15%) gels and one-dimensional 10% sodium do-
decyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) were performed
as described previously (Ugalde et al., 2004; Calvaruso et al., 2008). Lanes
were loaded with 40 or 80 mg of solubilized mitochondrial protein. Pottering
was performed as described in Vogel et al. (2005). Sonication and carbonate
treatments of mitochondria were performed as described previously (Ryan
et al., 2001). After electrophoresis, gels were processed for complex I In-Gel
Activity (CI-IGA) analysis or immunoblotting. For blotting, proteins were trans-
ferred to a PROTRAN nitrocellulose membrane (Schleicher &Schuell).
Antibodies and ECL Detection
Immunodetection was performed with the use of the following primary anti-
bodies: CI-NDUFS3, CI-NDUFA9 (Invitrogen), CI-ND1 (a gift from A. Lombes,
Unite de Recherche INSERM 153, Hospital de la Salpetriere, Paris, France),
CI-NDUFS2 (a gift from Brian Robinson, University of Toronto, Canada)
CII-SDHA, CIV-COX4, CIV-COX1, CV-subunit a (Mitosciences), CIII-core 2
(Invitrogen), NDUFAF1 (Vogel et al., 2005), ACAD9 (a gift from J. Vockley,
Mayo Clinic, Rochester, Minnesota, U.S.A.), Ecsit (a gift from M. Ryan, La
Trobe University, Melbourne, Australia), Cyclophilin B, MTHSP70 (Affinity Bio-
Reagents), cyt c, RFP (Abcam), MTP (a gift from R. Wanders, AMC Amster-
dam, The Netherlands), VLCAD (Abnova), and porin (VWR international).
Secondary antibody detection was performed using peroxidase-conjugated
anti-mouse or anti-rabbit IgGs (Invitrogen). The signal was generated using
ECL (Pierce, Rockford, USA).
Enzyme Measurements
The activities of the mitochondrial respiratory chain complexes were deter-
mined in cultured fibroblasts according to established procedures (Janssen
et al., 2007; Mourmans et al., 1997; Cooperstein and Lazarow, 1951;
Jonckheere et al., 2008). Values are expressed relative to the mitochondrial
reference enzyme citrate synthase and complex IV (Srere, 1969).
Molecular Genetic Studies
Genomic DNA from the index patient was prepared from cultured fibroblasts
using the method first described by Miller et al. (Miller et al., 1988). The
ACAD9 gene was amplified in 18 exons by the polymerase chain reactions.
Fragments included both DNA sequences of the individual exons, the splice
donor and splice acceptor sites. The sequences of the primers are available
upon request. The amplimers thus obtained were subjected to DNA sequence
analysis of the coding and noncoding strands (ENSG00000177646). PCR
products were purified with alkaline phosphatase and exonuclease
(Amersham, The Netherlands). Subsequently, a sequence reaction was per-
formed using the Ready reaction sequence mix (Applied Biosystems). After
the precipitation, the fragments were dissolved in Hi-Ditm Formamide (Applied
Biosystems) and sequenced by the ABI Prism 3130 Genetic Analyzer.
Sequence analyses were performed using Sequencer 4.2 software.
Complementation of Complex I-Deficient Fibroblasts
with Baculoviral Constructs
The ACAD9 pDONR201 (for creation of this vector, see above) was combined
with the pBac-DEST-RFP as described in Hoefs et al. (Hoefs et al., 2008).
RFP-tagged COX8 leader was cloned as described previously (Hoefs et al.,
2008). These constructs were then used to make baculovirus and perform
complementation as described previously (Hoefs et al., 2008).292 Cell Metabolism 12, 283–294, September 8, 2010 ª2010 ElseviePhylogeny
The phylogenetic distribution was assessed by constructing a phylogeny of
ACAD9 and its homologs from representative taxa in the metozoa. The tree
was rooted with a sequence from Anaerymyxobacter dehalogenans that is
a close bacterial relative to ACADVL. The maximum likelihood phylogeny
was calculated with PhyML (Guindon et al., 2005), using four gamma-distrib-
uted rate categories plus one estimated proportion of invariant sites and using
the LG (Le Gascuel) (Le and Gascuel, 2008) amino acid substitution matrix.
Bootstrap values larger than 90/100 are indicated and indicate a clear separa-
tion between the ACAD9 and ACADVL orthologous groups. This separation
is also supported by maximal bootstrap values in Neighbor Joining trees
generated with the identity matrix (data not shown) and was used to calculate
the ACAD9-specific residues (Figure 5A). GenBank identifiers of the
sequences used for the tree, from top to bottom, ACAD9: 21361497,
114589061, 109098063, 32469593, 197313734, 14623171, 73984516,
149728394, 126336530, 57524955, 148234611, 113671417. ACADVL:
160332360, 3273228, 23956084, 126309240, 197246590, 160774198,
219490408, 221121754, 196014217, 91076006, 24655582. Anaeromyxo-
bacter: 220919351.
Modeling
A homology model of ACAD9 was built using the structure of 3b96 human very
long-chain Acyl-CoA dehydrogenase (VLCAD) as a template. The sequences
of ACAD9 and the VLCAD share 47% sequence identity, enough to perform
homology modeling. The model was built using Yasara’s homology modeling
script (Krieger et al., 2004) with standard parameters. The multiple sequence
alignment of a series of ACAD9 and VLCAD proteins was made using ClustalX
(Larkin et al., 2007). We used the multi-Relief webserver to compare groups of
ACAD9 proteins to a group of VLCADs and to identify interesting amino acids
(Ye et al., 2008). Modeling details can be found online at http://www.cmbi.ru.
nl/hvensela/ACAD9/.
Palmitoyl-CoA Dehydrogenase Enzyme Measurements
After the siRNA transfection as described earlier (6-well format), palmitoyl-CoA
dehydrogenase activity was determined in homogenates of these HEK293
cells by using ferricenium hexafluorophosphate as electron acceptor followed
by HPLC to separate the different product acyl-CoA species (Lehman et al.,
1990). Palmitoyl-CoA was used as substrate. Short-chain hydroxyacyl-CoA
dehydrogenase activity was measured as a control enzyme using acetoace-
tyl-CoA as substrate. Both activities were measured in duplicate.
Fatty Acid Oxidation Measurements
HEK293 cells (23 104) were seeded in 250 ml DMEM supplemented with 10%
FCS (no antibiotics) per well in 48-well plates a day preceding the siRNA trans-
fection. The cells were transfected with siRNA duplex in the presence of 0.6 ml
DharmaFECT 1 (Thermo Fisher Scientific) and opti-Mem 1 (Invitrogen) to
achieve a final concentration of 100 nM in a total volume of 300 ml. Control:
cyclophilin B (Thermo Fisher Scientific), ACAD9 #1 and #2, VLCAD #1
and #2 (for sequences, see paragraph on RNA interference). The cells were
incubated at 37C in a CO2 incubator for 72 hr, and a second cycle of transfec-
tion was performed. At 72 hr after the second cycle of transfection, the fatty
acid oxidation of the cells was measured as described previously (Manning
et al., 1990). In brief, after the double siRNA transfection, the cells were incu-
bated in Krebs-Henseleit buffer containing 0.1% BSA (Sigma, fatty acid free),
100 mMoleic acid, a tracer of [9,10-3H(N)] oleic acid, and 500 mML-carnitine for
2 hr at 37C in a CO2 incubator. The reaction was stopped by applying the
incubation medium to an ion exchange column containing Dowex OH-
(1 3 8–200; Sigma). The exchange columns were washed twice with 1 ml
water, and subsequent liquid scintillation counting of the column flowthrough
determined radioactivity. Assayswere performed in quadruplicate (HEK293) or
triplicate (fibroblasts).
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
three figures, and one table and can be found with this article online at
doi:10.1016/j.cmet.2010.08.002.r Inc.
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